ACMJ
Anatolian Current Medical Journal

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

eISSN: 2718-0115
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
A biomarker for estimating no-reflow phenomenon in PCI-treated non-ST-segment elevation myocardial infarction patients: serum Cystatin C
Abstract
Aims: Cystatin C (Cys-C) is a biochemical marker associated not only with renal function but also with inflammatory processes. We aimed to investigate the relationship between the post-percutaneous coronary intervention (PCI) no-reflow phenomenon (NRP) and Cys-C in patients with non-ST-segment elevation acute coronary syndrome (NST-ACS).
Methods: This retrospective, single-center observational study consecutively enrolled patients who were hospitalized with a diagnosis of NST-ACS and underwent PCI between October 2021 and February 2022. Baseline characteristics, medications, admission laboratory parameters, and angiographic features were recorded. Logistic regression and sensitivity analyses were performed to identify parameters associated with NRP.
Results: Out of 199 patients (mean age: 62.0±10.3, 59.8% male), 36 (18.1%) developed NRP. Patients who developed NRP had a lower ejection fraction (49.7±10.3% vs. 53.5±7.1%, p=0.046) and were less likely to be male (36.1% vs. 65.0%, p=0.001). Additionally, individuals with NRP exhibited higher blood urea and C-reactive protein levels than those without NRP (p<0.05 for both). Similarly, serum Cys-C levels were elevated in the former group (1.44±0.57 vs. 1.07±0.40 mg/L, p=0.001). Multivariable logistic regression analysis demonstrated that Cys-C [odds ratio (OR)=4.793, p=0.014] and culprit lesion [OR=8.112, p=0.043 for LCx, OR=27.025, p=0.001 for RCA] were independently associated with NRP. Receiver operating characteristic curve analysis showed a cut-off point >1.1 mg/L for Cys-C determined NRP with 72.2% sensitivity and 66.9% specificity (area under the curve=0.711, p<0.001).
Conclusion: We have demonstrated a potential association between the serum Cys-C level at admission and the occurrence of NRP among NST-ACS patients undergoing PCI.

Keywords : Cystatin C, no-reflow phenomenon, non-ST-segment elevation acute coronary syndrome, percutaneous coronary intervention

Download Article


1. Lozano R, Naghavi M, Foreman K, et al. Global and regionalmortality from 235 causes of death for 20 age groups in 1990and 2010: a systematic analysis for the Global Burden of DiseaseStudy 2010. Lancet. 2012;380(9859):2095-2128.
2. Jernberg T, Lindahl B, James S, Larsson A, Hansson L-O, WallentinL. Cystatin C: a novel predictor of outcome in suspected orconfirmed non-ST-elevation acute coronary syndrome. Circ.2004;110(16):2342-2348.
3. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brainnatriuretic peptide and other risk markers for the separateprediction of mortality and subsequent myocardial infarctionin patients with unstable coronary artery disease: a GlobalUtilization of Strategies To Open occluded arteries (GUSTO)-IVsubstudy. Circ. 2003;108(3):275-281.
4. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score forunstable angina/non-ST elevation MI: a method for prognosticationand therapeutic decision making. JAMA. 2000;284(7):835-842.
5. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of deathand myocardial infarction in the six months after presentationwith acute coronary syndrome: prospective multinationalobservational study (GRACE). BMJ. 2006;333(7578):1091.
6. Stouffer GA, Lenihan D, Lerakis S, et al. Incidence andmanagement of &ldquo;no-reflow&rdquo; following percutaneous coronaryinterventions. Am J Med Sci. 2005;329(2):78-85.
7. Harbalıoğlu H, Gen&ccedil; &Ouml;, Alıcı G, Quisi A, Yıldırım A. Impact ofHAT2CH2 Score on the development of no-reflow phenomenonin patients with ST-segment elevation myocardial infarction.Angiol. 2024;75(1):44-53.
8. Fajar JK, Heriansyah T, Rohman MS. The predictors of noreflow phenomenon after percutaneous coronary intervention inpatients with ST elevation myocardial infarction: a meta-analysis.Indian Heart J. 2018;70(Suppl 3):S406-S418.
9. Dong-bao L, Qi H, Zhi L, Shan W, Wei-ying J. Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon duringemergency percutaneous coronary intervention for ST-elevatedacute myocardial infarction. Clin Cardiol. 2010;33(12):E7-E12.
10. Wong DT, Puri R, Richardson JD, Worthley MI, WorthleySG. Myocardial &lsquo;no-reflow&rsquo;&mdash;diagnosis, pathophysiology andtreatment. Int J Cardiol. 2013;167(5):1798-1806.
11. Zhou H, He X-y, Zhuang S-w, et al. Clinical and proceduralpredictors of no-reflow in patients with acute myocardialinfarction after primary percutaneous coronary intervention.World J Emerg Med. 2014;5(2):96.
12. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognosticvalue of no-reflow phenomenon after percutaneous coronaryintervention in patients with acute myocardial infarction. J AmColl Cardiol. 2010;55(21):2383-2389.
13. Mehta RH, Harjai KJ, Boura J, et al. Prognostic significance oftransient no-reflow during primary percutaneous coronaryintervention for ST-elevation acute myocardial infarction. Am JCardiol. 2003;92(12):1445-1447.
14. Mussap M, Plebani M. Biochemistry and clinical role of humancystatin C. Crit Rev Clin Lab Sci. 2004;41(5-6):467-550.
15. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimatorof glomerular filtration rate? Clin Chem. 2002;48(5):699-707.
16. Correa S, Morrow DA, Braunwald E, et al. Cystatin C for riskstratification in patients after an acute coronary syndrome. J AmHeart Assoc. 2018;7(20):e009077.
17. &Aring;kerblom A, Wallentin L, Siegbahn A, et al. Cystatin C andestimated glomerular filtration rate as predictors for adverseoutcome in patients with ST-elevation and non-ST-elevationacute coronary syndromes: results from the platelet inhibitionand patient outcomes study. Clin Chem. 2012;58(1):190-199.
18. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTSGuidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165.
19. Baumgartner H, Hung J, Bermejo J, et al. Recommendationson the echocardiographic assessment of aortic valve stenosis: afocused update from the European Association of CardiovascularImaging and the American Society of Echocardiography. EurHeart J Cardiovasc Imaging. 2017;18(3):254-275.
20. Gibson CM, Scho¨mig A. Coronary and myocardial angiography:angiographic assessment of both epicardial and myocardialperfusion. Circ. 2004;109(25):3096-3105.
21. Kirma C, Izgi A, Dundar C, et al. Clinical and proceduralpredictors of no-reflow phenomenon after primary percutaneouscoronary interventions experience at a single center. Circ J.2008;72(5):716-721.
22. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelinesfor the management of acute coronary syndromes: developed bythe task force on the management of acute coronary syndromesof the European Society of Cardiology (ESC). Eur Heart J.2023;44(38):3720-3826.
23. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Managementof no-reflow phenomenon in the catheterization laboratory.JACC: Cardiovasc Intervent. 2017;10(3):215-223.
24. Bouleti C, Mewton N, Germain S. The no-reflow phenomenon:state of the art. Arch Cardiovasc Dis. 2015;108(12):661-674.
25. Durante A, Camici PG. Novel insights into an &ldquo;old&rdquo; phenomenon:the no reflow. Int J Cardiol. 2015;187:273-280.
26. Kurtul A, Murat SN, Yarlioglues M, Duran M, Celik IE, Kilic A.Mild to moderate renal impairment is associated with no-reflowphenomenon after primary percutaneous coronary interventionin acute myocardial infarction. Angiol. 2015;66(7):644-651.
27. Pantsios C, Kapelios C, Vakrou S, et al. Effect of elevatedreperfusion pressure on &ldquo;no reflow&rdquo; area and infarct size in aporcine model of ischemia-reperfusion. J Cardiovasc PharmacolTher. 2016;21(4):405-411.
28. Ipek G, Onuk T, Karatas MB, et al. CHA2DS2-VASc score is apredictor of no-reflow in patients with st-segment elevationmyocardial infarction who underwent primary percutaneousintervention. Angiol. 2016;67(9):840-845.
29. Harding SA. The role of vasodilators in the prevention andtreatment of no-reflow following percutaneous coronaryintervention. Heart. 2006;92(9):1191-1193.
30. Cheng C, Liu XB, Bi SJ, Lu QH, Zhang J. Serum cystatin C levelsrelate to no-reflow phenomenon in percutaneous coronaryinterventions in ST-segment elevation myocardial infarction.PLoS One. 2019;14(8):e0220654.
31. Rofyda OF, Hussein SE, Rasha AT, et al. The relationship betweenthe levels of serum cystatin C and the occurrence of the no-reflow phenomenon during primary percutaneous coronaryinterventions. Med J Cairo Univ. 2023;91(06):897-908.
32. Cerne D, Kaplan-Pavlovcic S, Kranjec I, Jurgens G. Mildlyelevated serum creatinine concentration correlates with theextent of coronary atherosclerosis. Ren Fail. 2000;22(6):799-808.
33. Baigent C, Burbury K, Wheeler D. Premature cardiovasculardisease in chronic renal failure. Lancet. 2000;356(9224):147-152.
34. Lou B, Luo Y, Zhang H, et al. Association between cystatin C andCardiac function in acute myocardial infarction patients: a real-world analysis. Dis Markers. 2022;2022:7267937.
35. Suthahar N, Lau ES, Blaha MJ, et al. Sex-specific associations ofcardiovascular risk factors and biomarkers with incident heartfailure. J Am Coll Cardiol. 2020;76(12):1455-1465.
36. Pantea-Ro?an LR, Pantea VA, Bungau S, et al. No-reflow afterPPCI&mdash;a predictor of short-term outcomes in STEMI patients. JClin Med. 2020;9(9):2956.
37. Grubb A, Bjo¨rk J, Nyman U, et al. Cystatin C, a marker forsuccessful aging and glomerular filtration rate, is not influencedby inflammation. Scand J Clin Lab Invest. 2011;71(2):145-149.
38. Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW,Lindholt JS. Higher cystatin C level predicts long-termmortality in patients with peripheral arterial disease. Atheroscler.2011;216(2):440-445.
39. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidneyfunction and cardiovascular risk. Heart Fail Rev. 2012;17(2):251-261.
40. Niccoli G, Conte M, Della Bona R, et al. Cystatin C is associatedwith an increased coronary atherosclerotic burden and a stableplaque phenotype in patients with ischemic heart disease andnormal glomerular filtration rate. Atheroscler. 2008;198(2):373-380.
Article available in :
Volume 6, Issue 2, 2024
Page : 108-115
https://doi.org/10.38053/acmj.1410973
Article Information
Received : 29 Ara 2023
Accepted : 18 Oca 2024
Published : 08 Mar 2024
Corresponding Author :

Ömer Genç: Department of Cardiology, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkiye

[email protected]
Citation : Genç Ö, Yıldırım A, Erdoğan A. A biomarker for estimating no-reflow phenomenon in PCI-treated non-ST-segment elevation myocardial infarction patients: serum Cystatin C. Anatolian Curr Med J. 2024;6(2):108-115.

Read: 162
Cited: 0
Download : 203
_Footer